Injectables deal prospect drums up India's Claris
This article was originally published in Scrip
Renewed speculation around a potential sell-off of Claris Lifesciences' injectables business saw the firm's shares make strong gains on Indian bourses on 21 May, a day ahead of its scheduled earnings announcement.
You may also be interested in...
Baxter has snapped up India’s Claris Injectables, accelerating efforts to become a global leader in generic injectables. The deal also puts the spotlight back on the significant M&A appetite in the niche injectables segment and the scarcity premiums that such assets can command.
Hilleman CEO Davinder Gill is leaving the global vaccine R&D organization after eight years at the helm and several mileposts. Incoming CEO Raman Rao takes charge from 1 February.
Biocon and Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.